Nabumetone Capsules
Function and Efficacy
This product is a non-acidic non-steroidal anti-inflammatory drug, which is rapidly metabolized to 6-methoxy-2-naphthylacetic acid (6-MNA) in the liver and exerts antipyretic, analgesic and anti-inflammatory effects. 1 The anti-inflammatory, analgesic and antipyretic effects are related to the fact that the active metabolites of cabutimetone inhibit the synthesis of prostaglandins in inflammatory tissues. 2 Little effect on gastric mucosa: This product is a non-acidic, non-ionic prodrug, which has no obvious local direct effect on the gastric mucosa during the absorption process; at the same time, this product has little inhibitory effect on the physiological cyclooxygenase of the gastric mucosa. Therefore, the incidence of gastrointestinal mucosal erosion and bleeding caused by this product is low. 3 No effect on bleeding and coagulation: This product induces platelet count in vitro in blood samples of healthy volunteers.
Ingredients
The main ingredients and chemical names of this product are: The main ingredient is nabumetone, whose chemical name is 4-(6-methoxy-2-naphthyl)-2-butanone
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| NabumetoneIngredients |
This product is a non-acidic non-steroidal anti-inflammatory drug, and its active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA) has antipyretic, analgesic and anti-inflammatory effects. Its anti-inflammatory, analgesic and antipyretic effects are related to the inhibition of prostaglandin synthesis in inflammatory tissues; it has little effect on the gastric mucosa, and has no significant effect on the platelet function and coagulation mechanism induced in vitro in blood samples of healthy volunteers. More |
42924-53-8 | 27 |
Appearance
This product is a capsule. The content is white or off-white crystalline powder, odorless and tasteless.
Indication
Rheumatoid arthritis, osteoarthritis.
Usage and Dosage
1Usual dosage for adults: 1.0g (2 tablets) per day, once a day. Maximum daily dosage is 2g, divided into two doses. Adults weighing less than 50kg can start with 0.5g (1 tablet) per day. Gradually increase to the effective dose. 2The dosage for children has not yet been established.
Adverse Reactions
1 Gastrointestinal tract: nausea, vomiting, indigestion, diarrhea, abdominal pain and constipation, about 1% to 3%. Upper gastrointestinal bleeding, about 0.7%. In the cases using this product, the incidence of ulcers was 0.1% in the short-term treatment group (6 weeks to 6 months) and 0.95% in the long-term treatment group (8 years). The incidence of diarrhea increases with daily oral administration of 2g of nabumetone. 2 Nervous system: Manifestations include headache, dizziness, tinnitus, sweating, insomnia, drowsiness, tension and dreaming, with an incidence of less than 1.5%. 3 Skin: rash and itching, about 2.1%, edema, about 1.1%. 4 Rare or occasional adverse reactions include jaundice, abnormal liver function, anxiety, depression, paresthesia, tremor, dizziness,
Precautions
It is contraindicated for patients with active peptic ulcer or bleeding, severe liver function abnormalities, and allergies to this product and other non-steroidal anti-inflammatory drugs.
Special Population Medication
Precautions for children: Forbidden. Precautions for pregnancy and lactation: Pregnant women are not recommended to use this product in the last 3 months of pregnancy and during lactation. Precautions for the elderly: The elderly should maintain the lowest effective dose when using this product.
Drug Interactions
1. The absorption rate of this product is not affected by the combined use of aluminum hydroxide gel, aspirin or acetaminophen. However, it is generally not recommended to use two or more non-steroidal anti-inflammatory drugs at the same time. 2. There is no interaction between this product and the anticoagulant warfarin in healthy volunteers. However, there is no data on the combined use of these two drugs in patients. 3. When this product is used in combination with acetyl anticonvulsants and sulfonylurea hypoglycemic drugs, the dosage should be appropriately reduced.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
0.25g
Validity Period
36 months
Manufacturer
-
Founded in:
1993-05-18 -
Address:
No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing -
Tax NO.:
91500000450533779H -
Registered Funds:
595.987425 yuan -
Website:
-
Email: